Chronic liver diseases from varying etiologies generally lead to liver fibrosis and cirrhosis.
Among them, non-alcoholic fatty liver disease (NAFLD) affects roughly one-quarter of the …

Recent studies have demonstrated that tissue homeostasis and metabolic function are
dependent on distinct tissue-resident immune cells that form functional cell circuits with …

Atherosclerosis is driven by the expansion of cholesterol-loaded 'foamy'macrophages in the
arterial intima. Factors regulating foamy macrophage differentiation and survival in plaque …

In obesity, sustained adipose tissue (AT) inflammation constitutes a cellular memory that
limits the effectiveness of weight loss interventions. Yet, the impact of fasting regimens on …

Chronic liver diseases, primarily metabolic dysfunction-associated steatotic liver disease
(MASLD), harmful use of alcohol, or viral hepatitis, may result in liver fibrosis, cirrhosis, and …

Nonalcoholic fatty liver disease (NAFLD) is the most common liver pathology worldwide. In
mice and humans, NAFLD progression is characterized by the appearance of TREM2 …

Metabolic dysfunction–associated steatohepatitis (MASH), formerly known as nonalcoholic
steatohepatitis (NASH), is an advanced stage of metabolic fatty liver disease. The …

The process of dead cell clearance by phagocytic cells, called efferocytosis, prevents
inflammatory cell necrosis and promotes resolution and repair. Defective efferocytosis …

The escalating global prevalence of obesity and its intricate association with the
development of hepatocellular carcinoma (HCC) pose a substantial challenge to public …

Atherosclerosis is a chronic disease of the vascular wall driven by lipid accumulation and
inflammation in the intimal layer of arteries, and its main complications—myocardial …